These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 7592913

  • 61. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
    Virtanen SS, Sandholm J, Yegutkin G, Kalervo Väänänen H, Härkönen PL.
    Cell Biol Int; 2010 Aug; 34(8):815-26. PubMed ID: 20446922
    [Abstract] [Full Text] [Related]

  • 62. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
    Sebti SM, Hamilton AD.
    Pharmacol Ther; 1997 Aug; 74(1):103-14. PubMed ID: 9336018
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
    Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD.
    Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
    [Abstract] [Full Text] [Related]

  • 69. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.
    James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC.
    Science; 1993 Jun 25; 260(5116):1937-42. PubMed ID: 8316834
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Effect of inhibition of farnesylation and geranylgeranylation on renal fibrogenesis in vitro.
    Masterson R, Kelynack K, Hewitson T, Becker G.
    Nephron Exp Nephrol; 2006 Jun 25; 102(1):e19-29. PubMed ID: 16179803
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, Fleming JB, Trevino JG, Hamilton AD, Sebti SM.
    Clin Cancer Res; 2019 Oct 01; 25(19):5984-5996. PubMed ID: 31227505
    [Abstract] [Full Text] [Related]

  • 76. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I.
    Hicks KA, Hartman HL, Fierke CA.
    Biochemistry; 2005 Nov 22; 44(46):15325-33. PubMed ID: 16285736
    [Abstract] [Full Text] [Related]

  • 77. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE, Adekenov SM, Williams RM, Prashad N, Baker FL, Madden TL, Newman R.
    Oncol Rep; 2001 Nov 22; 8(1):173-9. PubMed ID: 11115593
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.